Traduction de «plaque sans traitement » (Français → Anglais) :

(Return tabled) Question No. 199 Ms. Kirsty Duncan: With regard to the development and operation of the Canadian Multiple Sclerosis Monitoring System (CMSMS) announced in March 2011: (a) what are the government's baseline assumptions for the CMSMS, (i) how many Canadians live with MS according to the government’s source, (ii) what is the government's source; (b) what have been the challenges in developing the system between March 2011 and today, (i) how has each challenge been overcome, (ii) what are the achievements to date, (iii) what milestones has the government planned between December 2013 and December 2015 and by what dates; (c) ...[+++] what is the cost of developing the system, broken down by costs to date; (d) how much money did the Canadian Institutes for Health Research (CIHR) contribute to the development of the CMSMS, (i) were there any other partners involved in the development of the system, (ii) if so, who are they, (iii) what has each contributed; (e) who was involved in the design and development of the CMSMS, (i) from what departments/institutions were they, (ii) were potential conflicts of interest declared and, if so, how; (f) what health information does the CMSMS track, specifically, with regard to (i) chronic cerebrospinal venous insufficiency (CCSVI), (ii) impacts of CCSVI treatment, including but not limited to use of the following scales, Expanded Disability Status Scale, Modified Fatigue Impact Scale, Multiple Sclerosis Impact Scale, and Multiple Sclerosis Quality of Life Inventory, (iii) pharmaceutical treatments for MS, (vi) adverse drug reactions by MS drug; (g) who is/was overseeing pilot testing, (i) who is/was responsible for ensuring that patient information is/was protected, (ii) who is/was responsible for the integrity of the results; (h) were ethical reviews for pilot testing necessary and, if so, on what date did each pilot site pass ethical review; (i) when is pilot testing expected to/did it take place and at which MS clinics ...

I find this particularly unusual since on March 23, 2011, the Minister of Health announced a new monitoring system for MS. This system will capture information to identify disease patterns and track treatments and long-term outcomes for people living with MS, including those who have undergone treatment for CCSVI.

Stop denying these vascular services to persons with MS. Today the government and Health Canada need to tell the Canadian and provincial medical associations that they must immediately direct their members to cease discrimination against persons with MS by denying them access to the services of vascular specialists, to establish screening, and to ensure treatment processes, even if we do have MS. We want this committee to take immediate action to ensure that those most affected are offered immediate screening and treatment on compassi ...[+++]onate grounds while tasking the researchers of this committee to undertake a review of research that has already been done, protocols that are already in place for screening, and protocols for treatment Ms. Radley, you are way over.

Stabilise the plate by treatment with a stabilising solution (in order to allow long term storage at 4 °C without loss of activity) and blot dry onto adsorbent material.

Note 2. When basic silica gel plates are used for separation of the alcoholic fraction, there is no need for the unsaponifiable substances to be treated with A1203.

The MS Society is bringing research from the test tube to people living with MS and there are now treatments for some forms of MS.